stockrow
Monday 9 November 2026
Export LRMR’s income statement to Excel — free account
Larimar Therapeutics, Inc.
LRMR- EPS
- +26.8%
- Free cash flow
- −127.6%
Quarter to June 2026, against a year earlier
2.39
0.07
+3.02%
Follow LRMR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
4.70 | 4.29 | 2.19 | 4.06 |
+8 more quarters Free account |
Net Debt/EBITDA |
4.51 | 6.44 | 2.14 | 3.53 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.41 | 1.51 | 0.62 | 0.60 | |
Capex/Depreciation |
0.46 | 0.00 | 0.00 | 0.10 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.43) | (0.50) | (0.53) | (0.37) | |
Cash per Share |
1.50 | 2.23 | 1.88 | 2.24 | |
Shareholders Equity per Share |
1.23 | 1.76 | 1.07 | 1.78 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.23 | 1.76 | 1.07 | 1.78 | |
Free Cash Flow |
(44.16) | (44.61) | (38.53) | (28.78) | |
Working Capital |
126.51 | 157.22 | 77.23 | 138.11 | |
Capital Expenditures |
(0.13) | — | 0.00 | (0.02) | |
Net Current Asset Value |
122.75 | 154.50 | 74.27 | 134.91 | |
| Other line items | |||||
Quick Ratio |
4.57 | 4.20 | 2.11 | 3.89 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.42) | (0.50) | (0.53) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
5.88 | 5.43 | 3.82 | 6.39 | |
Average Assets |
157.65 | 189.34 | 173.03 | 203.19 | |
Average Common Equity |
123.62 | 151.15 | 124.95 | 168.72 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates